{
    "nctId": "NCT04874935",
    "briefTitle": "The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer",
    "officialTitle": "The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 66,
    "primaryOutcomeMeasure": "Tumor Response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females with age \u2265 18 years old.\n* Newly diagnosed breast cancer patients.\n* Planned neoadjuvant chemotherapy.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Nursing mothers.\n* Active or uncontrolled infection.\n* Presence of another malignancies.\n* Inadequate blood picture.\n* Serum Creatinine more than 1.5 mg /dl.\n* AST and ALT more than 2.5 upper limit.\n* History of known hypersensitivity to lansoprazole.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}